What type of study is this?

This is a Quantitative Study study (also classified as: Animal Study).

October 10, 2025Molecular Medicine ReportsOpen Access

Ginsenoside Rh1 inhibits tumor growth in mice with colorectal cancer and depressive symptoms via modulation of the gut microbiota and tumor microenvironment

View Full Paper

Ask AI

Bookmark

Authors

Experimental analysis shows ginsenoside Rh1 improved cancer outcomes in mice, indicating a role for gut microbiota modulation.

Ginsenoside Rh1 significantly inhibited tumor growth in colorectal cancer mice models exposed to chronic restraint stress, and improved depressive symptoms.
Increased levels of brain 5-HT and reduced tumor necrosis factor-α were observed alongside improved cognitive function and reduced depressive-like behaviors.
Assessment using an established CRC xenograft mouse model revealed that Rh1 reshaped the immune microenvironment through T cell activation and dendritic cell maturation.
Findings suggest ginsenoside Rh1 could be a novel therapeutic approach for patients dealing with colorectal cancer and depression.

Dai et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark